Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874)

Marina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, Alberto Fumagalli, Donata Sartori, Chiara Ancona, Mario Airoldi, Gabriella Moretti, Corrado Ficorella, Valentina Arcangeli, Lucrezia Diodati, Alberto Zambelli, Antonio Febbraro, Daniele Generali, Mirco Pistelli, Ornella Garrone, Antonino Musolino, Patrizia Vici, Michela Maur, Lucia MentucciaNicla La Verde, Giulia Bianchi, Salvatore Artale, Livio Blasi, Michela Piezzo, Francesco Atzori, Anna Turletti, Chiara Benedetto, Maria Concetta Cursano, Alessandra Fabi, Vittorio Gebbia, Antonio Schirone, Raffaella Palumbo, Antonella Ferzi, Antonio Frassoldati, Claudio Scavelli, Luca Clivio

Research output: Contribution to journalComment/debatepeer-review

Abstract

© 2018 Impact Journals LLC. All rights reserved. This article has been corrected: The correct author names are given below: Chiara Ancona and Michela Piezzo.
Original languageEnglish
Pages (from-to)34639-34640
Number of pages2
JournalOncotarget
Volume9
Issue number77
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint Dive into the research topics of 'Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874)'. Together they form a unique fingerprint.

Cite this